VivoSim Labs, Inc. (VIVS) News
Follow VivoSim Labs, Inc. (VIVS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
VIVS - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
VIVS - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
NEWS | Sep 16, 2026, 12:05 PM UTC
L
VivoSim Labs to add rat liver model to NAMkind platform
VivoSim Labs plans to add a rat liver model to its NAMkind platform.
EQUITY | Sep 01, 2026, 12:05 PM UTC
L
SEC Filings: Multiple Companies
Multiple companies file with SEC
EQUITY | Aug 03, 2026, 09:28 AM UTC
L
VIVS Sees Volatility
VIVS experiences volatility
EQUITY | Jul 31, 2026, 11:24 AM UTC
H
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Shares of Callan JMB Inc (NASDAQ: CJMB ) rose sharply in pre-market trading following the announcement that Callan JMB signed a strategic partnership with Alabama State University to build an integrated pharmaceutical ma
MACRO | Jul 17, 2026, 08:48 AM UTC
H
Why Vivosim Labs Shares Are Rocketing on Wednesday?
VivoSim Labs, Inc. (NASDAQ: VIVS ) shares are up on Wednesday as the company disclosed a significant milestone payment from Eli Lilly and Company (NYSE: LLY ) and provided optimistic revenue guidance for FY2027. The stoc
RATES | Jul 15, 2026, 03:20 PM UTC
H
VivoSim Labs Anticipates 500% Revenue Growth In FY27; Receives $5M Milestone Payment From Eli Lilly
VivoSim Labs, Inc. (Nasdaq: VIVS ) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027
EARNINGS | Jul 15, 2026, 12:09 PM UTC
H
VivoSim Labs To Present Data Demonstrating Its 3D Human Tissue Models In Two Presentations At The European Society Of Toxicology Annual Conf
The presentations collectively showcase the best-in-industry predictive power of VivoSim's proprietary AI-enabled NAMkind™ Liver and NAMkind™ GI platforms. In liver toxicology testing, across a set of compounds where ani
GEOPOLITICS | Jun 29, 2026, 12:10 PM UTC